Knight Therapeutics Continues to Demonstrate Winning Strategy; Files Investor Presentation, Launches Microsite

MONTREAL, April 08, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, announced today it has filed an investor presentation on SEDAR and on its website in connection with its 2019 Annual Meeting of Shareholders (the “Meeting”) scheduled for Tuesday, May 7, 2019.

In the presentation, Knight provides details about the Company’s track record of success under the stewardship of an experienced and highly qualified board of directors; highlights Knight’s clear and disciplined growth strategy for Canada and the rest-of-the-world; and outlines why activist shareholder Meir Jakobsohn’s self-motivated scheme to take control of Knight’s cash and board with unqualified directors will put shareholders’ investments at risk.

“Knight has been operating since 2014 with a clear and consistent strategy to build the leading Canadian and rest-of-the-world speciality pharmaceutical company. We have not and will not deviate from that strategy nor will we rush to make deals that don’t create value or create unnecessary risk for our investors,” said CEO Jonathan Goodman. “Meir Jakobsohn just doesn’t get it.  His latest plan is riddled with inconsistencies and evidences a lack of understanding of the Canadian market dynamic.  None of his nominees have experience in building a business whereas our team is made up of successful business builders with a proven track record.”

For Knight investors the choice is clear: Choose the experienced board that is executing on a proven strategy, not a board that has been cobbled together by Meir Jakobsohn to enable him to use Knight’s money to take unnecessary risk for his own benefit.

The investor presentation is available on Knight’s newly-launched microsite, [-knight.com/Shareholder-Voting], which consists of Meeting materials and information about management’s director nominees, and their vision for Knight.  The microsite also includes a video to help guide shareholders through the process of voting their shares.

PROTECT YOUR INVESTMENT – VOTE YOUR BLUE PROXY TODAY

We encourage shareholders to read the investor presentation, visit our microsite, and vote the BLUE Proxy or Voting Instruction Form (VIF) FOR the Knight board nominees who are aligned with your interests and the original vision of Knight.

Mr. Jakobsohn, his nominees, and his agenda have different objectives than Jonathan, you, and your investment.  Do not risk handing them control of your company.

The deadline to vote is Friday, May 3, 2019 at 5:00 p.m. (EST). Shareholders with questions regarding voting the BLUE Proxy or VIF should contact Knight's strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors, who can be reached by toll-free telephone in North America at 1-888-518-1552, by collect call outside North America at 416-867-2272, or by email at .

Advisors

Knight has retained Kingsdale Advisors as its strategic shareholder and communications advisor, Davies Ward Phillips & Vineberg LLP as its legal advisor, and RBC Capital Markets as its financial advisor.

About Knight Therapeutics Inc. 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at  or .

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2018. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.

CONTACT INFORMATION:

Investor Contact:

Knight Therapeutics Inc.

Samira Sakhia

President & Chief Financial Officer

T: 514-678-8930

F: 514-481-4116

 

 

Media Contact:

Kingsdale Advisors

Ian Robertson

Executive Vice President, Communication Strategy

Direct: 416-867-2333

Cell: 647-621-2646